<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; MRK</title>
	<atom:link href="http://www.stockbloghub.com/tag/mrk/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(PCE) GDP Headline Weak &#8211; Stronger Underneath</title>
		<link>http://www.stockbloghub.com/2012/04/28/pce-gdp-headline-weak-stronger-underneath/99812</link>
		<comments>http://www.stockbloghub.com/2012/04/28/pce-gdp-headline-weak-stronger-underneath/99812#comments</comments>
		<pubDate>Sat, 28 Apr 2012 20:06:53 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Financial]]></category>
		<category><![CDATA[Property Management]]></category>
		<category><![CDATA[Amazon.com Inc]]></category>
		<category><![CDATA[AMZN]]></category>
		<category><![CDATA[Arizona Land Income Corporation]]></category>
		<category><![CDATA[EXPE]]></category>
		<category><![CDATA[Expedia Inc.]]></category>
		<category><![CDATA[F]]></category>
		<category><![CDATA[Ford Motor Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[PCE]]></category>
		<category><![CDATA[PG]]></category>
		<category><![CDATA[Procter & Gamble Company]]></category>
		<category><![CDATA[SBUX]]></category>
		<category><![CDATA[Starbucks Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=99812</guid>
		<description><![CDATA[The rating downgrade of Spain and a slew of broadly favorable earnings reports will try to grab investors’ attention today, but they are unlikely to take the spotlight away from this morning’s mixed first quarter GDP report. Despite the GDP reading’s strong internals, the ‘headline’ miss will likely be the major driver of today’s trading action. The disappointing aspect of the report is that it is not weak enough to warrant Fed action, but also not strong enough to make investors feel good about the Fed economy. My overall takeaway from the report is that looking at it from the perspective of ‘what Bernanke will do,’ it is not QE-friendly. In its first read on the fourth quarter of 2011, the commerce department reported that the U.S. economy expanded at ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/28/pce-gdp-headline-weak-stronger-underneath/99812/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PCE) Ahead of Wall Street &#8211; April 27, 2012 &#8211; Ahead of Wall Street</title>
		<link>http://www.stockbloghub.com/2012/04/28/pce-ahead-of-wall-street-april-27-2012-ahead-of-wall-street/99810</link>
		<comments>http://www.stockbloghub.com/2012/04/28/pce-ahead-of-wall-street-april-27-2012-ahead-of-wall-street/99810#comments</comments>
		<pubDate>Sat, 28 Apr 2012 20:02:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Financial]]></category>
		<category><![CDATA[Property Management]]></category>
		<category><![CDATA[Amazon.com Inc]]></category>
		<category><![CDATA[AMZN]]></category>
		<category><![CDATA[Arizona Land Income Corporation]]></category>
		<category><![CDATA[EXPE]]></category>
		<category><![CDATA[Expedia Inc.]]></category>
		<category><![CDATA[F]]></category>
		<category><![CDATA[Ford Motor Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[PCE]]></category>
		<category><![CDATA[PG]]></category>
		<category><![CDATA[Procter & Gamble Company]]></category>
		<category><![CDATA[SBUX]]></category>
		<category><![CDATA[Starbucks Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=99810</guid>
		<description><![CDATA[Friday, April 27, 2012 The rating downgrade of Spain and a slew of broadly favorable earnings reports will try to grab investors’ attention today, but they are unlikely to take the spotlight away from this morning’s mixed first quarter GDP report. Despite the GDP reading’s strong internals, the ‘headline’ miss will likely be the major driver of today’s trading action. The disappointing aspect of the report is that it is not weak enough to warrant Fed action, but also not strong enough to make investors feel good about the Fed economy. My overall takeaway from the report is that looking at it from the perspective of ‘what Bernanke will do,’ it is not QE-friendly. In its first read on the fourth quarter of 2011, the commerce department reported that the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/28/pce-ahead-of-wall-street-april-27-2012-ahead-of-wall-street/99810/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Healthcare Reform: Bad News for Big Pharma?</title>
		<link>http://www.stockbloghub.com/2012/04/04/jnj-healthcare-reform-bad-news-for-big-pharma/97425</link>
		<comments>http://www.stockbloghub.com/2012/04/04/jnj-healthcare-reform-bad-news-for-big-pharma/97425#comments</comments>
		<pubDate>Wed, 04 Apr 2012 16:56:03 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=97425</guid>
		<description><![CDATA[Healthcare reform could be a minefield for Big Pharma in the long run. The Patient Protection and Affordable Care Act – less fondly known as “Obamacare” – was the big story to close out the month of March, as the Supreme Court officially took the case. In an effort to figure out which way the vote was going to swing, the media analyzed every word, pause and twitch the justices made. Though all of that heavy-duty analysis doesn’t actually prove anything; while the Court has likely already decided the healthcare mandate’s fate one way or the other, “We the People” probably won’t find out until June. Considering the political left’s repeated complaints about Solicitor General Donald Verrilli Jr. and Deputy Attorney General Edwin S. Kneedler’s admittedly painful performance in explaining ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/04/jnj-healthcare-reform-bad-news-for-big-pharma/97425/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(DNDN) Dendreon&#8217;s Provenge Showing Bleak Outlook</title>
		<link>http://www.stockbloghub.com/2012/03/05/dndn-dendreons-provenge-showing-bleak-outlook/93847</link>
		<comments>http://www.stockbloghub.com/2012/03/05/dndn-dendreons-provenge-showing-bleak-outlook/93847#comments</comments>
		<pubDate>Mon, 05 Mar 2012 15:19:26 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Dendreon Corporation]]></category>
		<category><![CDATA[DNDN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDVN]]></category>
		<category><![CDATA[Medivation Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=93847</guid>
		<description><![CDATA[Dendreon Corporation (DNDN) reported fourth-quarter 2011 earnings (including stock-based compensation expense but excluding other special items) of 37 cents per share, in contrast to the Zacks Consensus Estimate loss of 31 cents and year-ago loss of 60 cents per share. Full-year loss of $1.68 per share (excluding special items but including stock-based compensation expense) were narrower than the Zacks Consensus Estimate of a loss of $2.83 and the year-ago loss of $3.07 per share. Total revenue in the reported quarter climbed to $202.1 million from $25.0 million in the comparable quarter of 2010. We note, however, that revenue in the reported quarter included one time royalty revenue of $125 million related to sale of its royalty interest in Merck, Inc.’s (MRK) hepatitis C product Victrelis. Excluding this one-time revenue, Dendreon ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/03/05/dndn-dendreons-provenge-showing-bleak-outlook/93847/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BRO) Company News for February 7, 2012 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2012/02/07/bro-company-news-for-february-7-2012-corporate-summary/91396</link>
		<comments>http://www.stockbloghub.com/2012/02/07/bro-company-news-for-february-7-2012-corporate-summary/91396#comments</comments>
		<pubDate>Tue, 07 Feb 2012 18:38:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Financial]]></category>
		<category><![CDATA[Insurance Brokers]]></category>
		<category><![CDATA[BRO]]></category>
		<category><![CDATA[Brown & Brown Inc.]]></category>
		<category><![CDATA[CHUX]]></category>
		<category><![CDATA[CNSL]]></category>
		<category><![CDATA[Consolidated Communications Holdings Inc]]></category>
		<category><![CDATA[DEPO]]></category>
		<category><![CDATA[DepoMed Inc]]></category>
		<category><![CDATA[Fidelity National Financial Inc]]></category>
		<category><![CDATA[FNF]]></category>
		<category><![CDATA[LAZ]]></category>
		<category><![CDATA[Lazard Limited]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[O'Charley's Inc.]]></category>
		<category><![CDATA[SureWest Communications]]></category>
		<category><![CDATA[SURW]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=91396</guid>
		<description><![CDATA[•    Pharma company Depomed Inc&#8217;s. (NASDAQ:DEPO) shares advanced 5.37% after the company said it would receive royalties from Merck &#38; Co&#8217;s (NYSE:MRK) type 2 diabetes drug, Janumet XR •    Share prices of HCA Holdings Inc. (NYSE:HCA) rose 7.33% to close at $28.40 after the hospital chain reported its fourth-quarter earnings results. Separately, it also announced that it would be paying a special dividend of $2 per share •    Shares of Lazard Ltd. (NSE:LAZ) fell 4.22% after the investment bank&#8217;s fourth-quarter earnings figures came in behind analysts’ expectations •    Share prices of restaurant operator O’Charley’s Inc. (NASDAQ:CHUX) surged 41.96% a share after the company said it would be bought by Fidelity National Inc. (NYSE:FNF) •    Consolidated Communications Holdings Inc. (NASDAQ:CNSL) announced its plans to acquire telecom provider SureWest Communications (NASDAQ:SURW) for ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/02/07/bro-company-news-for-february-7-2012-corporate-summary/91396/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb Company Kicks Off 2012 Pharma Deals</title>
		<link>http://www.stockbloghub.com/2012/01/09/bmy-bristol-myers-squibb-company-kicks-off-2012-pharma-deals/89883</link>
		<comments>http://www.stockbloghub.com/2012/01/09/bmy-bristol-myers-squibb-company-kicks-off-2012-pharma-deals/89883#comments</comments>
		<pubDate>Mon, 09 Jan 2012 16:34:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Inhibitex Inc]]></category>
		<category><![CDATA[INHX]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Pharmasset Inc]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[VRUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=89883</guid>
		<description><![CDATA[The spate of acquisitions in the pharma industry continues in 2012 with Bristol-Myers Squibb Company (BMY) announcing the first major deal of the new year. Major merger and acquisition (M&#38;A) deals have taken place in the pharma sector over the last couple of years. With most of the big pharma players already facing or likely to face generic threats to their key products, the companies are resorting to M&#38;As and in-licensing deals to counter the loss of revenues that will arise following the genericization of its key drugs. Pharma major Bristol-Myers is no exception as the generic threat looms over many of its key drugs, including the blockbuster blood-thinner Plavix, co-developed with Sanofi (SNY). Bristol-Myers is looking to combat the generic threat through partnering deals and acquisitions, and is introducing ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/09/bmy-bristol-myers-squibb-company-kicks-off-2012-pharma-deals/89883/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Pharma &amp; Biotech Stock Review &amp; Outlook &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/12/29/jnj-pharma-biotech-stock-review-outlook-industry-outlook/89365</link>
		<comments>http://www.stockbloghub.com/2011/12/29/jnj-pharma-biotech-stock-review-outlook-industry-outlook/89365#comments</comments>
		<pubDate>Thu, 29 Dec 2011 15:55:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[DENTSPLY International Inc]]></category>
		<category><![CDATA[Elan Corporation plc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[ELN]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[HGSI]]></category>
		<category><![CDATA[Human Genome Sciences Inc.]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>
		<category><![CDATA[XRAY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=89365</guid>
		<description><![CDATA[With 2011 coming to an end, the pharmaceutical industry continues to face challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. All these factors will lead to a slowdown in global pharmaceutical market growth in the next five years, with major revenue-generating drugs like Lipitor, Plavix, Lexapro and Zyprexa losing exclusivity. In fact, by the end of 2011, drugs worth more than a total of $30 billion will lose patent protection. This includes drugs like Lipitor, Zyprexa and Levaquin. The effect of the genericization of these products will be felt mostly in 2012, which will be a challenging year for several companies. At the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/29/jnj-pharma-biotech-stock-review-outlook-industry-outlook/89365/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(XRT) Stock Market News for December 14, 2011 &#8211; Market News</title>
		<link>http://www.stockbloghub.com/2011/12/14/xrt-stock-market-news-for-december-14-2011-market-news/88581</link>
		<comments>http://www.stockbloghub.com/2011/12/14/xrt-stock-market-news-for-december-14-2011-market-news/88581#comments</comments>
		<pubDate>Wed, 14 Dec 2011 19:47:54 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Exchange Traded Fund]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[AA]]></category>
		<category><![CDATA[Alcoa Inc.]]></category>
		<category><![CDATA[BA]]></category>
		<category><![CDATA[BAC]]></category>
		<category><![CDATA[Bank of America Corporation]]></category>
		<category><![CDATA[Boeing Company]]></category>
		<category><![CDATA[Bon-Ton Stores Inc.]]></category>
		<category><![CDATA[BONT]]></category>
		<category><![CDATA[CAT]]></category>
		<category><![CDATA[Caterpillar Inc.]]></category>
		<category><![CDATA[J. C. Penney Company Inc]]></category>
		<category><![CDATA[JCP]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[M]]></category>
		<category><![CDATA[Macy's Inc.]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Saks Incorporated]]></category>
		<category><![CDATA[Sears Holdings Corporation]]></category>
		<category><![CDATA[SHLD]]></category>
		<category><![CDATA[SKS]]></category>
		<category><![CDATA[SPDR S&P Retail]]></category>
		<category><![CDATA[XRT]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88581</guid>
		<description><![CDATA[Markets eroded initial gains on Tuesday after it emerged that the Federal Reserve had no new gifts to offer to the economy. The central bank also cautioned that the global financial scenario poses a serious threat for the domestic economy. Additionally, with the pre-holiday rush supposedly setting in, a less than expected increase in retail sales acted as a deterrent to optimism among investors. The Dow Jones Industrial Average (DJIA) declined 0.6% to finish the day at 11,954.94. The Standard &#38; Poor 500 (S&#38;P 500) was down 0.9% and closed the day at 1,225.73. The tech-laden Nasdaq Composite Index settled at 2,579.27, sliding 1.3% lower. The fear-gauge CBOE Volatility Index (VIX) inched down a percentage to settle at 25.41, and reflected a lower level of concern for the second consecutive ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/14/xrt-stock-market-news-for-december-14-2011-market-news/88581/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EU) Emerging Markets: The Way Forward</title>
		<link>http://www.stockbloghub.com/2011/12/07/eu-emerging-markets-the-way-forward/88206</link>
		<comments>http://www.stockbloghub.com/2011/12/07/eu-emerging-markets-the-way-forward/88206#comments</comments>
		<pubDate>Wed, 07 Dec 2011 21:57:17 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Exchange Traded Fund]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88206</guid>
		<description><![CDATA[According to Irish orator, philosopher, &#38; politician Edmund Burke, change is the most powerful law of nature. The winds of change seem to be sweeping across the pharmaceutical industry as well. Until recently, most commercialization efforts were focused on the U.S. &#8212; the largest pharmaceutical market &#8212; along with Europe and Japan. However, with factors like pricing pressure in the European Union (EU) and intensifying generic competition affecting sales in large pharmaceutical markets, many leading players in the pharmaceutical space such as Pfizer (PFE), Bristol &#8211; Myers Squibb Company (BMY), Merck (MRK), Eli Lilly (LLY), GlaxoSmithKline (GSK), Astra Zeneca (AZN) and Sanofi-Aventis (SNY), have shifted their focus on emerging (&#8220;pharmerging&#8221;) markets. The key emerging markets targeted by big players in the pharmaceutical space (aka “Big Pharma&#8221;) include China, Russia, Brazil, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/07/eu-emerging-markets-the-way-forward/88206/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Spotlight on Hepatitis-C Market</title>
		<link>http://www.stockbloghub.com/2011/12/07/jnj-spotlight-on-hepatitis-c-market/88141</link>
		<comments>http://www.stockbloghub.com/2011/12/07/jnj-spotlight-on-hepatitis-c-market/88141#comments</comments>
		<pubDate>Wed, 07 Dec 2011 17:52:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Pharmasset Inc]]></category>
		<category><![CDATA[SVR]]></category>
		<category><![CDATA[Syniverse Holdings Inc.]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[VRUS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88141</guid>
		<description><![CDATA[Is the hepatitis-C market the next Mecca for the pharma/biotech sector? It seems so if we go by the flurry of activity and heightened interest in this market in the past few quarters. The hepatitis-C virus (HCV) market seems to have caught the eye of several pharma/biotech companies &#8211; as evident by the deals being signed for the development of drugs for the treatment of HCV. We are talking about the recent announcements made by big players like Johnson &#38; Johnson (JNJ), Bristol-Myers Squibb (BMY) and Gilead Sciences, Inc. (GILD). All three companies have made it clear they want a piece of the HCV market pie. Johnson &#38; Johnson’s Tibotec Pharmaceuticals and Bristol-Myers Squibb recently announced that they have decided to join forces for the development of Bristol-Myers’ daclatasvir (BMS-790052) ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/07/jnj-spotlight-on-hepatitis-c-market/88141/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Completes Trial Enrollment</title>
		<link>http://www.stockbloghub.com/2011/12/02/alny-alnylam-pharmaceuticals-completes-trial-enrollment/87898</link>
		<comments>http://www.stockbloghub.com/2011/12/02/alny-alnylam-pharmaceuticals-completes-trial-enrollment/87898#comments</comments>
		<pubDate>Fri, 02 Dec 2011 16:19:15 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87898</guid>
		<description><![CDATA[Alnylam Pharmaceuticals Inc. (ALNY) recently announced it has completed enrollment in a mid-stage study of its pipeline candidate ALN-RSV01, an RNA interference technology (RNAi) therapeutic being studied for the treatment of respiratory syncytial virus (RSV) infection. The study is being conducted in RSV-infected lung transplant patients at 33 lung transplant centers in six countries. Data from the study is expected in mid-2012. Alnylam is developing ALN-RSV01 on its own while Cubist Pharmaceuticals (CBST) has the opt-in right to collaborate with the company in future for the lung transplant indication. Kyowa Hakko Kirin has opt-in rights for the candidate in Asia. Alnylam’s RNAi technology is potentially revolutionary. Alnylam is utilizing this know-how for selectively turning off the activity of certain genes to build a pipeline of drug candidates to treat a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/02/alny-alnylam-pharmaceuticals-completes-trial-enrollment/87898/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Reveals ALNTTR01 Trial Data</title>
		<link>http://www.stockbloghub.com/2011/11/28/alny-alnylam-pharmaceuticals-reveals-alnttr01-trial-data/87547</link>
		<comments>http://www.stockbloghub.com/2011/11/28/alny-alnylam-pharmaceuticals-reveals-alnttr01-trial-data/87547#comments</comments>
		<pubDate>Mon, 28 Nov 2011 16:32:53 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87547</guid>
		<description><![CDATA[Alnylam Pharmaceuticals Inc. (ALNY) recently presented data from an early stage study of its pipeline candidate ALN-TTR01 at a scientific conference in Japan. ALN-TTR01 is a systemically delivered RNA interference technology (RNAi) therapeutic that employs a first-generation lipid nanoparticles (LNP) formulation to treat transthyretin (TTR) mediated amyloidosis (ATTR). Data from the trials showed that ALN-TTR01 led to statistically significant reductions in serum TTR protein levels for the treatment of ATTR. Overall, the candidate has proved to be well tolerated with no serious adverse events observed in the study. We believe the encouraging data further highlights the potential of RNAi as a new class of therapeutics. This is the first time an RNAi has silenced a disease-causing gene in clinical trials. ALN-TTR01 is part of Alnylam’s core product strategy, Alnylam 5&#215;15, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/28/alny-alnylam-pharmaceuticals-reveals-alnttr01-trial-data/87547/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(DNDN) Dendreon Loss Narrows</title>
		<link>http://www.stockbloghub.com/2011/11/06/dndn-dendreon-loss-narrows/86549</link>
		<comments>http://www.stockbloghub.com/2011/11/06/dndn-dendreon-loss-narrows/86549#comments</comments>
		<pubDate>Sun, 06 Nov 2011 19:55:48 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CMS]]></category>
		<category><![CDATA[CMS Energy Corporation]]></category>
		<category><![CDATA[Dendreon Corporation]]></category>
		<category><![CDATA[DNDN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[MDVN]]></category>
		<category><![CDATA[Medivation Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86549</guid>
		<description><![CDATA[Dendreon Corporation (DNDN) reported third-quarter 2011 loss (including stock-based compensation expense but excluding other special items) of 67 cents per share, which was narrower than the Zacks Consensus Estimate of 70 cents due to a slightly better-than-expected performance of its prostate cancer vaccine Provenge in the quarter. Loss was, however, much wider than the year-ago loss of 54 cents per share. Quarterly Details Total revenue in the reported quarter climbed to $64.3 million (including rebates and charge-backs) from $20.2 million in the comparable quarter of 2010. The jump was attributable to the higher Provenge revenue in the current quarter versus low Provenge sales in the third quarter of 2010 as it was only the second quarter of its launch. Revenues were also above the Zacks Consensus Estimate of $63 million. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/06/dndn-dendreon-loss-narrows/86549/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMD) Company News for October 31, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/11/02/amd-company-news-for-october-31-2011-corporate-summary/86187</link>
		<comments>http://www.stockbloghub.com/2011/11/02/amd-company-news-for-october-31-2011-corporate-summary/86187#comments</comments>
		<pubDate>Wed, 02 Nov 2011 21:04:39 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Semiconductor - Broad Line]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Advanced Micro Devices Inc.]]></category>
		<category><![CDATA[AMD]]></category>
		<category><![CDATA[BBBY]]></category>
		<category><![CDATA[Bed Bath & Beyond Inc.]]></category>
		<category><![CDATA[Chevron Corporation]]></category>
		<category><![CDATA[CVX]]></category>
		<category><![CDATA[Goodyear Tire & Rubber Company]]></category>
		<category><![CDATA[GT]]></category>
		<category><![CDATA[Hewlett-Packard Company]]></category>
		<category><![CDATA[HPQ]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[Whirlpool Corporation]]></category>
		<category><![CDATA[WHR]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86187</guid>
		<description><![CDATA[•    Advanced Micro Devices, Inc. (NYSE:AMD) posted third quarter earnings of $0.13 per share, ahead of the Zacks Consensus Estimate of $0.10 per share •    Goodyear Tire &#38; Rubber Co. (NYSE:GT) reported a profit of $161 million or $0.60 per share in the third quarter of 2011. Excluding special items, profits were $195 million or $0.72 per share, higher than the Zacks Consensus Estimate of $0.25 per share •    Merck &#38; Co. Inc. (NYSE:MRK) posted third quarter 2011 earnings per share (excluding special items) of $0.94, beating the Zacks Consensus Estimate of $0.91 per share •    Chevron Corporation (NYSE:CVX) reported third quarter 2011 results earnings per share (excluding adjustments for foreign-currency effects) of $3.69, significantly higher than the Zacks Consensus Estimate of $3.42 •    Whirlpool Corp. (NYSE:WHR) announced that it ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/02/amd-company-news-for-october-31-2011-corporate-summary/86187/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PRGO) Perrigo Beats Earnings Forecast &#8211; Sales Miss</title>
		<link>http://www.stockbloghub.com/2011/11/02/prgo-perrigo-beats-earnings-forecast-sales-miss/86198</link>
		<comments>http://www.stockbloghub.com/2011/11/02/prgo-perrigo-beats-earnings-forecast-sales-miss/86198#comments</comments>
		<pubDate>Wed, 02 Nov 2011 21:04:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Advanced Photonix Inc.]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86198</guid>
		<description><![CDATA[Perrigo Company (PRGO) reported earnings per share of $1.10 for the first quarter of fiscal 2012, beating the Zacks Consensus Estimate of $1.03 and the year-earlier earnings of 87 cents per share. Light sales performance was offset by a lower tax rate to drive earnings growth. First quarter revenues increased approximately 13% over the prior year to $725.3 million. Total revenues were, however, below the Zacks Consensus Estimate of $748 million. Strong performances by the Active Pharmaceutical Ingredients (API) and Rx Pharmaceuticals segments were offset by sluggish revenues from the company’s Nutritional and Consumer Healthcare businesses due to competitive pressures. The First Quarter of Fiscal 2012 in Detail The revenue performance in the quarter from four of the company’s businesses is detailed below. Consumer Healthcare (CHC): Perrigo reported CHC revenue ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/02/prgo-perrigo-beats-earnings-forecast-sales-miss/86198/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AA) Stock Market News for October 12, 2011 &#8211; Market News</title>
		<link>http://www.stockbloghub.com/2011/10/12/aa-stock-market-news-for-october-12-2011-market-news/84953</link>
		<comments>http://www.stockbloghub.com/2011/10/12/aa-stock-market-news-for-october-12-2011-market-news/84953#comments</comments>
		<pubDate>Wed, 12 Oct 2011 17:59:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Aluminum]]></category>
		<category><![CDATA[Basic Materials]]></category>
		<category><![CDATA[AA]]></category>
		<category><![CDATA[Alcoa Inc.]]></category>
		<category><![CDATA[AT&T Inc.]]></category>
		<category><![CDATA[Chevron Corporation]]></category>
		<category><![CDATA[CVX]]></category>
		<category><![CDATA[DIS]]></category>
		<category><![CDATA[GE]]></category>
		<category><![CDATA[General Electric Company]]></category>
		<category><![CDATA[IBM]]></category>
		<category><![CDATA[International Business Machines]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[T]]></category>
		<category><![CDATA[The Travelers Companies Inc.]]></category>
		<category><![CDATA[TRV]]></category>
		<category><![CDATA[Verizon Communications Inc.]]></category>
		<category><![CDATA[VZ]]></category>
		<category><![CDATA[Walt Disney Company]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=84953</guid>
		<description><![CDATA[On Tuesday, markets ended mixed after trading in a tight range throughout the day, as investors anxiously waited for Slovakia’s vote for or against bolstering Europe&#8217;s financial rescue plan. Investors also eagerly awaitedAlcoa’s quarterly results, which would kick-start the third quarter earnings season. The Dow Jones Industrial Average (DJIA) fluctuated between small gains and losses to finally end at 11,416.3, dropping roughly 0.2%. The Standard &#38; Poor 500 (S&#38;P 500) declined by less than 0.1% to finish the day at 1,195.54. The Nasdaq Composite Index gained 0.7% to close at 2,583.03. The fear-gauge CBOE Volatility Index (VIX) hovered below 33. Advancers outnumbered the decliners on the NYSE by a ratio of 2,199 to 1,719. The 17-point movement for the Dow was in stark contrast to the blue-chip’s recent trend of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/10/12/aa-stock-market-news-for-october-12-2011-market-news/84953/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Announces Pipeline Progress</title>
		<link>http://www.stockbloghub.com/2011/10/06/alny-alnylam-pharmaceuticals-announces-pipeline-progress-at-alnylam/84757</link>
		<comments>http://www.stockbloghub.com/2011/10/06/alny-alnylam-pharmaceuticals-announces-pipeline-progress-at-alnylam/84757#comments</comments>
		<pubDate>Thu, 06 Oct 2011 23:38:53 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[HD]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[The Home Depot Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=84757</guid>
		<description><![CDATA[Recently, Alnylam Pharmaceuticals Inc. (ALNY) announced the commencement of an early-stage stage study (n~32) of its RNAi (RNA (Ribo Nucleic Acid) interference) therapeutic program ALN-PCS for treating patients suffering from hypercholesterolemia. Hypercholesterolemia indicates a situation where the cholesterol levels in the blood are higher than normal. The randomized, single-blind, placebo-controlled, single-ascending dose study intends to evaluate the safety and tolerability of the candidate in patients suffering from high low-density lipoprotein cholesterol (LDLc or “bad” cholesterol). Moreover, the clinical activity of ALN-PCS is also expected to be assessed through the study on the basis of measurements of plasma PCSK9 protein and serum LDLc. Results from the study, which is being conducted in the UK, are expected by year end. ALN-PCS is a part of Alnylam’s core product strategy &#8211; 5&#215;15 introduced ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/10/06/alny-alnylam-pharmaceuticals-announces-pipeline-progress-at-alnylam/84757/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ENZN) Enzon Pharmaceuticals Plans a 50% Workforce Cut</title>
		<link>http://www.stockbloghub.com/2011/09/27/enzn-enzon-pharmaceuticals-plans-a-50-workforce-cut/84114</link>
		<comments>http://www.stockbloghub.com/2011/09/27/enzn-enzon-pharmaceuticals-plans-a-50-workforce-cut/84114#comments</comments>
		<pubDate>Tue, 27 Sep 2011 20:45:43 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ENZN]]></category>
		<category><![CDATA[Enzon Pharmaceuticals Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=84114</guid>
		<description><![CDATA[Enzon Pharmaceuticals (ENZN) recently announced that it will reduce its workforce by almost half to better align its resources with much tempered pipeline activities. The research and development pipeline at Enzon was reduced drastically in the last few months. During the second quarter, Enzon announced that it will no longer develop three messenger ribonucleic acid (mRNA) antagonists utilizing the LNA technology and returned the rights to Santaris. The mRNA antagonists, all of which were in phase I trials, were hypoxia-inducible factor-1 alpha (HIF-1 a) indicated for tumors and lymphoma, survivin indicated for cancer and pediatric patients with relapse acute lymphoblastic leukemia and androgen receptor (AR) for castration-resistant prostate cancer (CRPC). Earlier, in mid-May 2011, Enzon announced plans to halt the development of its lead pipeline candidate PEG-SN38 for the treatment ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/27/enzn-enzon-pharmaceuticals-plans-a-50-workforce-cut/84114/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(EU) Pharmaceuticals Stock Outlook &#8211; September 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/09/23/eu-pharmaceuticals-stock-outlook-september-2011-industry-outlook/83930</link>
		<comments>http://www.stockbloghub.com/2011/09/23/eu-pharmaceuticals-stock-outlook-september-2011-industry-outlook/83930#comments</comments>
		<pubDate>Fri, 23 Sep 2011 18:59:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Exchange Traded Fund]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Endo Pharmaceuticals Holdings Inc]]></category>
		<category><![CDATA[ENDP]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ICAgen Inc]]></category>
		<category><![CDATA[ICGN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[ONXX]]></category>
		<category><![CDATA[Onyx Pharmaceuticals Inc]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WisdomTree Dreyfus Euro]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83930</guid>
		<description><![CDATA[The pharmaceutical industry continues to be impacted by major issues such as sluggish prescription trends, European Union (EU) pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to witness a significant imbalance between new product launches and patent expirations. All these factors will lead to a slowdown in global pharmaceutical market growth in the next five years. Major revenue generating drugs like Lipitor, Plavix, Lexapro and Zyprexa are expected to confront generic competition over the next five years. In fact, revenues in excess of $30 billion are expected to be lost in 2011 itself due to key drugs like Lipitor and Zyprexa going off-patent. The impact of the genericization of these drugs will be felt significantly in 2012, which will be a challenging year ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/23/eu-pharmaceuticals-stock-outlook-september-2011-industry-outlook/83930/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MRK) Merck Drug Candidate Presents New Data</title>
		<link>http://www.stockbloghub.com/2011/09/21/mrk-merck-drug-candidate-presents-new-data/83706</link>
		<comments>http://www.stockbloghub.com/2011/09/21/mrk-merck-drug-candidate-presents-new-data/83706#comments</comments>
		<pubDate>Wed, 21 Sep 2011 18:08:08 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83706</guid>
		<description><![CDATA[Merck (MRK) recently presented new clinical and pre-clinical data on its phase III pipeline candidate, odanacatib. Odanacatib is an investigational cathepsin K (cat-K) inhibitor which is being developed for the treatment of osteoporosis in post-menopausal women. Results were presented from a phase IIb clinical study extending to five years. Merck said that postmenopausal women being treated with odanacatib 50 mg weekly continuously for five years experienced an increase in bone mass density (BMD) at the lumbar spine (11.9% increase from baseline), femoral neck (9.8% increase from baseline), hip trochanter (10.9% increase from baseline), and total hip (8.5% increase from baseline). However, adverse and serious adverse experiences were higher in the odanacatib treatment group. Adverse experiences and serious adverse experiences were 89% and 22%, respectively in the odanacatib arm, compared to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/21/mrk-merck-drug-candidate-presents-new-data/83706/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AZN) AstraZeneca Coverage Initiated at Neutral</title>
		<link>http://www.stockbloghub.com/2011/09/21/azn-astrazeneca-coverage-initiated-at-neutral/83692</link>
		<comments>http://www.stockbloghub.com/2011/09/21/azn-astrazeneca-coverage-initiated-at-neutral/83692#comments</comments>
		<pubDate>Wed, 21 Sep 2011 14:56:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACS]]></category>
		<category><![CDATA[Affiliated Computer Services Inc]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83692</guid>
		<description><![CDATA[We are initiating coverage on AstraZeneca (AZN) with a Neutral recommendation and a target price of $47.00. AstraZeneca, headquartered in London, UK, is one of the largest biopharmaceutical companies in the world. AstraZeneca’s business can be broken down into separate lines based on therapeutic classes. These include: gastrointestinal, cardiovascular, respiratory and inflammation, oncology, neuroscience, infection and other. The company’s key products include Crestor (cholesterol management); Nexium (acid reflux); Seroquel (schizophrenia and bipolar mania); Atacand (hypertension and symptomatic heart failure), Arimidex (breast cancer), Zoladex (prostate and breast cancer) and Symbicort (asthma). We are impressed by the performance of lead drug Crestor which is primarily responsible for AstraZeneca being one of the leading players in the global cardiovascular market. The US launch of Brilinta (ticagrelor) for the reduction of the rate of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/21/azn-astrazeneca-coverage-initiated-at-neutral/83692/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol-Myers Squibb Presents HCV Data</title>
		<link>http://www.stockbloghub.com/2011/09/20/bmy-bristol-myers-squibb-presents-hcv-data/83567</link>
		<comments>http://www.stockbloghub.com/2011/09/20/bmy-bristol-myers-squibb-presents-hcv-data/83567#comments</comments>
		<pubDate>Tue, 20 Sep 2011 19:50:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83567</guid>
		<description><![CDATA[Recently, Bristol-Myers Squibb Company (BMY) presented encouraging data from a phase II study (n=48) which evaluated its candidate BMS-790052 in combination with peginterferon and ribavirin (standards of care) for treating patients suffering from the hepatitis C virus (HCV). Bristol-Myers presented data from the mid-stage study at the 51st interscience conference on antimicrobial agents and chemotherapy held in the US. The double-blind study evaluated BMS-790052 at three doses (3 mg, 10 mg or 60 mg) in treatment-naïve patients infected with genotype 1 chronic HCV. Results from the study revealed that the rate of SVR24 (sustained virologic response – absence of detectable HCV at 24 weeks post treatment ) achieved by patients treated with a combination of BMS-790052, PEG-interferon alfa and ribavirin was higher across all evaluated doses than those receiving placebo ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/20/bmy-bristol-myers-squibb-presents-hcv-data/83567/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVO) Novo Nordisk Data Presented at European Association for the Study of Diabetes</title>
		<link>http://www.stockbloghub.com/2011/09/19/nvo-novo-nordisk-data-presented-at-european-association-for-the-study-of-diabetes/83265</link>
		<comments>http://www.stockbloghub.com/2011/09/19/nvo-novo-nordisk-data-presented-at-european-association-for-the-study-of-diabetes/83265#comments</comments>
		<pubDate>Mon, 19 Sep 2011 20:38:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83265</guid>
		<description><![CDATA[Novo Nordisk (NVO) recently presented data from two trials of its lead diabetes drug, Victoza, at the European Association for the Study of Diabetes (EASD). The first trial showed that using Victoza at an early stage in diabetes treatment of patients with type II diabetes, who had not received any treatment before or previously received only one oral anti-diabetic drug (OAD), led to greater improvements in glycaemic control than those who had been dosed two or more OAD’s. The second trial showed that when type II diabetes patients switched from oral treatment with Merck’s (MRK) Januvia to injectable Victoza (once daily) experienced increased treatment satisfaction as well as significant reductions in blood glucose and body weight. We remind investors that in June this year, Novo Nordisk had presented data from ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/19/nvo-novo-nordisk-data-presented-at-european-association-for-the-study-of-diabetes/83265/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ENZN) Enzon Pharmaceuticals Analyst Downgrades Shares to Sell</title>
		<link>http://www.stockbloghub.com/2011/09/15/enzn-enzon-pharmaceuticals-analyst-downgrades-shares-to-sell/83032</link>
		<comments>http://www.stockbloghub.com/2011/09/15/enzn-enzon-pharmaceuticals-analyst-downgrades-shares-to-sell/83032#comments</comments>
		<pubDate>Thu, 15 Sep 2011 17:49:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ENZN]]></category>
		<category><![CDATA[Enzon Pharmaceuticals Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=83032</guid>
		<description><![CDATA[We recently downgraded our rating on Enzon Pharmaceuticals Inc. (ENZN) from Neutral to Underperform with a target price of $9.50. In mid-May 2011, Enzon announced plans to halt the development of its lead pipeline compound PEG-SN38 (EZN-2208), a PEGylated version of the active metabolite of the cancer drug, irinotecan, for the treatment of metastatic colorectal cancer (mCRC). Enzon decided to halt development as the company intends to focus its resources on other areas with nearer-term commercial potential. The discontinuation of development of PEG-SN38 for mCRC is a disappointment, leaving the company with just one clinical program in mid-stage development (PEG-SN38 for metastatic breast cancer) and all others in early stages of development. The company’s pipeline candidates include PEG-SN38, hypoxia-inducible factor1 (HIF-1) alpha, survivin antagonists and multiple messenger RNA (mRNA) antagonists ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/15/enzn-enzon-pharmaceuticals-analyst-downgrades-shares-to-sell/83032/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SCR) Simcere Drug Cleared in China</title>
		<link>http://www.stockbloghub.com/2011/09/01/scr-simcere-drug-cleared-in-china/82262</link>
		<comments>http://www.stockbloghub.com/2011/09/01/scr-simcere-drug-cleared-in-china/82262#comments</comments>
		<pubDate>Thu, 01 Sep 2011 17:26:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RA]]></category>
		<category><![CDATA[Railamerica Inc]]></category>
		<category><![CDATA[SCR]]></category>
		<category><![CDATA[Simcere Pharmaceutical Group.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82262</guid>
		<description><![CDATA[Recently, the State Food and Drug Administration (SFDA) of China delivered a boost to Simcere Pharmaceutical Group (SCR) by clearing its drug Iremod, for treating patients suffering from active rheumatoid arthritis (RA). Iremod, developed solely by Simcere, will be the first Iguratimod drug to hit the global market and will be used mainly to treat patients suffering from active RA. Iguratimod refers to a new disease-modifying, anti-rheumatoid therapy and belongs to the category of Disease Modifying Anti-rheumatic Drugs (DMARDs). The approval of Iremod by the Chinese regulatory authorities will not only boost Simcere’s top line but also widen the treatment options for patients suffering from the dreaded disease, whose incidence is on the rise. Iremod will operate in a highly lucrative market and will compete with players like Bristol-Myers (BMY), ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/01/scr-simcere-drug-cleared-in-china/82262/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Analyst Maintains Neutral Rating on Shares</title>
		<link>http://www.stockbloghub.com/2011/08/30/alny-alnylam-pharmaceuticals-analyst-maintains-neutral-rating-on-shares/82322</link>
		<comments>http://www.stockbloghub.com/2011/08/30/alny-alnylam-pharmaceuticals-analyst-maintains-neutral-rating-on-shares/82322#comments</comments>
		<pubDate>Tue, 30 Aug 2011 21:15:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82322</guid>
		<description><![CDATA[We have maintained a Neutral rating on Alnylam Pharmaceuticals, Inc (ALNY) with a target price of $7.00 per share. Alnylam Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapeutics based on a biological breakthrough technology known as RNA (Ribo Nucleic Acid) interference (RNAi). Alnylam is currently utilizing this know-how to build a pipeline of drug candidates for the treatment of a wide array of diseases. Alnylam Pharmaceuticals Inc.’s second quarter 2011 loss of 33 cents per share was narrower than the Zacks Consensus Estimate of a loss of 37 cents per share and the year-ago loss of 35 cents per share. Lower operating expenses led to the narrower loss despite lukewarm revenues in the quarter. Revenues for the reported quarter fell 22.6% from the prior year to $20.6 million. Revenues ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/30/alny-alnylam-pharmaceuticals-analyst-maintains-neutral-rating-on-shares/82322/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GDP) Stock Market News for August 22, 2011 &#8211; Market News</title>
		<link>http://www.stockbloghub.com/2011/08/22/gdp-stock-market-news-for-august-22-2011-market-news/81776</link>
		<comments>http://www.stockbloghub.com/2011/08/22/gdp-stock-market-news-for-august-22-2011-market-news/81776#comments</comments>
		<pubDate>Mon, 22 Aug 2011 17:06:05 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Basic Materials]]></category>
		<category><![CDATA[Independent Oil & Gas]]></category>
		<category><![CDATA[AAPL]]></category>
		<category><![CDATA[American Express Company]]></category>
		<category><![CDATA[Apple Inc.]]></category>
		<category><![CDATA[AXP]]></category>
		<category><![CDATA[Chevron Corporation]]></category>
		<category><![CDATA[Cisco Systems]]></category>
		<category><![CDATA[CSCO]]></category>
		<category><![CDATA[CVX]]></category>
		<category><![CDATA[GDP]]></category>
		<category><![CDATA[Goodrich Petroleum Corporation]]></category>
		<category><![CDATA[Hewlett-Packard Company]]></category>
		<category><![CDATA[HPQ]]></category>
		<category><![CDATA[IBM]]></category>
		<category><![CDATA[INTC]]></category>
		<category><![CDATA[Intel Corporation]]></category>
		<category><![CDATA[International Business Machines]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[MCD]]></category>
		<category><![CDATA[McDonald's Corporation]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[Microsoft Corporation]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MSFT]]></category>
		<category><![CDATA[PG]]></category>
		<category><![CDATA[Procter & Gamble Company]]></category>
		<category><![CDATA[Wal-Mart Stores Inc.]]></category>
		<category><![CDATA[WMT]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=81776</guid>
		<description><![CDATA[Fears of a global downturn dragged the markets down on Friday and benchmarks registered their fourth consecutive week of losses. While recession worries in US unnerved investors, fears of financial destabilization on the European front strengthened the bearish mood. Posting its 10th move of over 100 points in the last 15 trading days, the Dow Jones Industrial Average (DJIA) shed 172 points or 1.6% to close at 10,817.65. The Standard &#38; Poor 500 (S&#38;P 500) slipped 1.5% to settle at 1,123.53. The Nasdaq Composite Index dropped 1.6% to finish the day at 2,341.84. The fear-gauge CBOE Volatility Index (VIX) settled over 43 and is far ahead of the technical level of 30. On the New York Stock Exchange, consolidated volumes were 5.16 billion shares. For every one stock that moved ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/22/gdp-stock-market-news-for-august-22-2011-market-news/81776/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GILD) Take Advantage of the Fire Sale in Healthcare</title>
		<link>http://www.stockbloghub.com/2011/08/18/gild-take-advantage-of-the-fire-sale-in-healthcare/81490</link>
		<comments>http://www.stockbloghub.com/2011/08/18/gild-take-advantage-of-the-fire-sale-in-healthcare/81490#comments</comments>
		<pubDate>Fri, 19 Aug 2011 00:47:13 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Kindred Healthcare Inc.]]></category>
		<category><![CDATA[KND]]></category>
		<category><![CDATA[Lexicon Pharmaceuticals Inc]]></category>
		<category><![CDATA[LXRX]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[NUVA]]></category>
		<category><![CDATA[NuVasive Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=81490</guid>
		<description><![CDATA[by Marc Lichtenfeld, Investment U Senior Analyst Wednesday, August 17, 2011: Issue #1580 The market’s violent sell-off over the past two weeks took down many good stocks along with the bad ones. Even with the quick bounce, quality companies are still trading at steep discounts to where they were just two weeks ago and are now at very attractive valuations. This is especially true in the healthcare sector, where names like Gilead Sciences (Nasdaq: GILD), which is down 12 percent, are still below where they were trading prior to the debt crisis decline. Whether the United States’ debt is rated AAA or AA+ should have no bearing on sales of Gilead’s leading HIV drugs or whether its newest drug, Quad, will receive FDA approval. The stock trades at just 11.2 times ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/18/gild-take-advantage-of-the-fire-sale-in-healthcare/81490/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SCR) Simcere Pharmaceutical Group Beats on Bottom Line</title>
		<link>http://www.stockbloghub.com/2011/08/16/scr-simcere-pharmaceutical-group-beats-on-bottom-line/81398</link>
		<comments>http://www.stockbloghub.com/2011/08/16/scr-simcere-pharmaceutical-group-beats-on-bottom-line/81398#comments</comments>
		<pubDate>Tue, 16 Aug 2011 17:01:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ADS]]></category>
		<category><![CDATA[Alliance Data Systems Corporation]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[SCR]]></category>
		<category><![CDATA[Simcere Pharmaceutical Group.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=81398</guid>
		<description><![CDATA[Simcere Pharmaceutical Group’s (SCR) second quarter 2011 earnings of 21 cents per American Depositary Share (ADS) surpassed the Zacks Consensus Estimate of 13 cents and the year-ago earnings of 10 cents. Increased revenues and lower share count helped boost earnings. Revenues Revenues at Simcere Pharma came in at $84.4 million in the second quarter, up 0.3% year over year in local currency. Revenues however fell short of the Zacks Consensus Estimate of $89 million. Higher sales of drugs, Endu (up 30.3% in local currency to $10.8 million), Sinofuan (up 25.8% in local currency to $8.2 million) and edaravone injection products (up 12.7% in local currency to $33.7 million) helped boost revenues. Other Details Gross margin declined to 84.9% during the quarter, compared with 86.8% in the prior-year quarter. A rise ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/16/scr-simcere-pharmaceutical-group-beats-on-bottom-line/81398/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ENZN) Enzon Pharmaceuticals&#8217; Weak Top Line Widens Loss</title>
		<link>http://www.stockbloghub.com/2011/08/09/enzn-enzon-pharmaceuticals-weak-top-line-widens-loss/80950</link>
		<comments>http://www.stockbloghub.com/2011/08/09/enzn-enzon-pharmaceuticals-weak-top-line-widens-loss/80950#comments</comments>
		<pubDate>Tue, 09 Aug 2011 19:23:45 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ENZN]]></category>
		<category><![CDATA[Enzon Pharmaceuticals Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80950</guid>
		<description><![CDATA[Enzon Pharmaceuticals’ (ENZN) second quarter 2011 net loss of 12 cents per share (excluding restructuring charge) was wider than the loss of 8 cents suffered in the year-ago quarter as the decline in royalty revenue neutralized the savings from cost-cutting initiatives. The Zacks Consensus Estimate indicated a break-even for the company. Total revenue at Enzon was $9.6 million, sharply down 30% year over year due to the decline in royalty revenue. Revenue was also much below the Zacks Consensus Estimate of $15 million. Royalty revenue in the quarter dropped around 13% to $9.2 million. Enzon earns the majority of its royalty revenue from the sale of PegIntron, marketed by Merck &#38; Co. (MRK), for treating patients suffering from hepatitis C virus (HCV). The decline in royalty revenue in the reported ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/09/enzn-enzon-pharmaceuticals-weak-top-line-widens-loss/80950/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(XLF) Stock Market News for August 9, 2011 &#8211; Market News</title>
		<link>http://www.stockbloghub.com/2011/08/09/xlf-stock-market-news-for-august-9-2011-market-news/80949</link>
		<comments>http://www.stockbloghub.com/2011/08/09/xlf-stock-market-news-for-august-9-2011-market-news/80949#comments</comments>
		<pubDate>Tue, 09 Aug 2011 19:10:17 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Exchange Traded Fund]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[AA]]></category>
		<category><![CDATA[Alcoa Inc.]]></category>
		<category><![CDATA[American Express Company]]></category>
		<category><![CDATA[AXP]]></category>
		<category><![CDATA[BAC]]></category>
		<category><![CDATA[Bank of America Corporation]]></category>
		<category><![CDATA[CAT]]></category>
		<category><![CDATA[Caterpillar Inc.]]></category>
		<category><![CDATA[Chevron Corporation]]></category>
		<category><![CDATA[ConocoPhillips]]></category>
		<category><![CDATA[COP]]></category>
		<category><![CDATA[CVX]]></category>
		<category><![CDATA[Exxon Mobil Corporation]]></category>
		<category><![CDATA[Financial Select Sector SPDR]]></category>
		<category><![CDATA[GE]]></category>
		<category><![CDATA[General Electric Company]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[Marathon Oil Corporation]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MRO]]></category>
		<category><![CDATA[PBR]]></category>
		<category><![CDATA[Petroleo Brasileiro]]></category>
		<category><![CDATA[The Travelers Companies Inc.]]></category>
		<category><![CDATA[TRV]]></category>
		<category><![CDATA[Verizon Communications Inc.]]></category>
		<category><![CDATA[VZ]]></category>
		<category><![CDATA[XLF]]></category>
		<category><![CDATA[XOM]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80949</guid>
		<description><![CDATA[Standard &#38; Poor’s downgraded the US credit rating by a notch, delivering a crushing blow to benchmarks on Monday. Tension from the other side of the Atlantic also dampened sentiment as Europe was gripped by debt woes. Investors also struggled to find a clear answer about whether the recent turmoil means that another recession is in the offing, at a time when the economy is yet to recover from the last one. The credit rating agency’s decision came in on Friday last week after the closing bells. Monday was thus the first trading day after the downgrade, and almost immediately benchmarks ended up in the red. This is the first time that the US has lost its AAA rating since 1917. The Dow Jones Industrial Average (DJIA) posted its sixth-worst ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/09/xlf-stock-market-news-for-august-9-2011-market-news/80949/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMGN) Company News for August 1, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/08/01/amgn-company-news-for-august-1-2011-corporate-summary/80308</link>
		<comments>http://www.stockbloghub.com/2011/08/01/amgn-company-news-for-august-1-2011-corporate-summary/80308#comments</comments>
		<pubDate>Mon, 01 Aug 2011 16:40:03 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AmeriGas Partners LP]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[APU]]></category>
		<category><![CDATA[C]]></category>
		<category><![CDATA[Chevron Corporation]]></category>
		<category><![CDATA[Citigroup Inc.]]></category>
		<category><![CDATA[CVX]]></category>
		<category><![CDATA[Eagle Bulk Shipping Inc]]></category>
		<category><![CDATA[EGLE]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Newell Rubbermaid Inc.]]></category>
		<category><![CDATA[NWL]]></category>
		<category><![CDATA[Southwest Gas Corporation]]></category>
		<category><![CDATA[STEC]]></category>
		<category><![CDATA[STEC Inc.]]></category>
		<category><![CDATA[SWX]]></category>
		<category><![CDATA[Wells Fargo & Company]]></category>
		<category><![CDATA[WFC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80308</guid>
		<description><![CDATA[•    Chevron Corp. (NYSE:CVX) reported a jump in its second-quarter 2011 profits, benefiting from higher oil prices and stronger refining margins. Earnings per share (excluding adjustments for foreign-currency effects) came in at $3.89, beating the Zacks Consensus Estimate of $3.55 and the year-ago adjusted profit of $2.58 •    Amgen Inc. (NASDAQ:AMGN) reported second quarter earnings per share of $1.35, above the Zacks Consensus Estimate of $1.30, and 0.7% higher than year-ago earnings •    Merck &#38; Co. Inc.’s (NYSE:MRK)  earnings per share (excluding special items) for the second quarter of 2011 came in at 95 cents, in line with the Zacks Consensus Estimate, but 10.5% above year-ago earnings. •    Newell Rubbermaid Inc. (NYSE:NWL) reported second quarter of 2011 earnings of $0.46 per share, down from $0.51 a share in the year-ago ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/01/amgn-company-news-for-august-1-2011-corporate-summary/80308/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMGN) Debt Ceiling Debate and Dismal GDP Add To Market Stress</title>
		<link>http://www.stockbloghub.com/2011/07/31/amgn-debt-ceiling-debate-and-dismal-gdp-add-to-market-stress/80203</link>
		<comments>http://www.stockbloghub.com/2011/07/31/amgn-debt-ceiling-debate-and-dismal-gdp-add-to-market-stress/80203#comments</comments>
		<pubDate>Sun, 31 Jul 2011 19:36:55 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ACI]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[Arch Coal Inc]]></category>
		<category><![CDATA[Chevron Corporation]]></category>
		<category><![CDATA[CVX]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[NEM]]></category>
		<category><![CDATA[Newmont Mining Corporation]]></category>
		<category><![CDATA[SBUX]]></category>
		<category><![CDATA[Starbucks Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80203</guid>
		<description><![CDATA[The debt debate continues to steal the spotlight from earnings and economic reports. The stock market has lost ground in recent days due to this uncertain environment even as corporate earnings reports have broadly come ahead of expectations. With both sides in the debt debate sticking to their positions ahead of the Tuesday deadline, stocks will likely remain on edge today as well. The dismal GDP adds to the market&#8217;s woes. While the GDP report was expected to be on the soft side, the extent of the weakness and the negative revisions to the prior quarter&#8217;s numbers were very disappointing. The U.S. economy expanded at a lower-than-expected 1.3% rate in the second quarter, while the first quarter&#8217;s growth rate was sharply revised down to 0.4% from 1.9%. The softness is ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/31/amgn-debt-ceiling-debate-and-dismal-gdp-add-to-market-stress/80203/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMGN) Amgen Beats Earnings Expectations &#8211; Updates Outlook</title>
		<link>http://www.stockbloghub.com/2011/07/30/amgn-amgen-beats-earnings-expectations-updates-outlook/80227</link>
		<comments>http://www.stockbloghub.com/2011/07/30/amgn-amgen-beats-earnings-expectations-updates-outlook/80227#comments</comments>
		<pubDate>Sat, 30 Jul 2011 19:54:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[Energy Services of America Corporation]]></category>
		<category><![CDATA[ESA]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80227</guid>
		<description><![CDATA[Amgen (AMGN) reported second quarter earnings per share of $1.35, 5 cents above the Zacks Consensus Estimate and 0.7% above the year-ago earnings. Total revenues increased 4% to $3,959 million in the second quarter of 2011. Revenues topped the Zacks Consensus Estimate of $3,778 million. US revenues increased 7% during the quarter to $2,975 million. Meanwhile, international revenues increased 11% to $918 million. Foreign exchange (Fx) fluctuation boosted revenues by $34 million during the second quarter. The Quarter in Detail Second quarter total product sales increased 8% to $3,893 million. Revenues of Amgen’s erythropoiesis-stimulating agent (ESA) Aranesp fell 3% to $585 million (US: $241 million, down 10%; ex-US: $344 million, up 2%). US sales were down mainly due to a decline in demand that was partially offset by a price ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/30/amgn-amgen-beats-earnings-expectations-updates-outlook/80227/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(XLF) Stock Market News for July 19, 2011 &#8211; Market News</title>
		<link>http://www.stockbloghub.com/2011/07/19/xlf-stock-market-news-for-july-19-2011-market-news/79349</link>
		<comments>http://www.stockbloghub.com/2011/07/19/xlf-stock-market-news-for-july-19-2011-market-news/79349#comments</comments>
		<pubDate>Tue, 19 Jul 2011 18:41:43 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Exchange Traded Fund]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[AA]]></category>
		<category><![CDATA[Alcoa Inc.]]></category>
		<category><![CDATA[BA]]></category>
		<category><![CDATA[BAC]]></category>
		<category><![CDATA[Bank of America Corporation]]></category>
		<category><![CDATA[Barclays plc]]></category>
		<category><![CDATA[BCS]]></category>
		<category><![CDATA[Boeing Company]]></category>
		<category><![CDATA[Chevron Corporation]]></category>
		<category><![CDATA[Credit Suisse Group]]></category>
		<category><![CDATA[CS]]></category>
		<category><![CDATA[CVX]]></category>
		<category><![CDATA[DB]]></category>
		<category><![CDATA[Deutsche Bank AG]]></category>
		<category><![CDATA[Financial Select Sector SPDR]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[HAL]]></category>
		<category><![CDATA[Halliburton Company]]></category>
		<category><![CDATA[IBM]]></category>
		<category><![CDATA[International Business Machines]]></category>
		<category><![CDATA[JEF]]></category>
		<category><![CDATA[Jefferies Group Inc.]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[UBS]]></category>
		<category><![CDATA[UBS AG]]></category>
		<category><![CDATA[XLF]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=79349</guid>
		<description><![CDATA[Lingering euro-zone debt worries and the impasse over debt-ceiling negotiations weighed down investor sentiment on Monday, while bank shares felt the burn of the markets’ downtrend. The Dow Jones Industrial Average (DJIA) shed 0.8% to close at 12,385.16. The Standard &#38; Poor 500 (S&#38;P 500) slipped to 1,305.44, after dropping 0.8%. The Nasdaq Composite Index dropped 0.9% to settle at 2,765.11. The fear-gauge CBOE Volatility Index (VIX) recorded a surge of over 10% to trade slightly lower than 21. On the New York Stock Exchange, NYSE Amex and Nasdaq, consolidated volumes were 6.89 billion shares compared with the daily average of 7.49 billion. On the NYSE, for every five stocks that declined, only one stock moved up. Among the 30 Dow components, only Chevron Corp. (NYSE:CVX) managed to finish in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/19/xlf-stock-market-news-for-july-19-2011-market-news/79349/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MRK) Japanese Approval for Merck Products</title>
		<link>http://www.stockbloghub.com/2011/07/11/mrk-japanese-approval-for-merck-products/78598</link>
		<comments>http://www.stockbloghub.com/2011/07/11/mrk-japanese-approval-for-merck-products/78598#comments</comments>
		<pubDate>Mon, 11 Jul 2011 15:54:46 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78598</guid>
		<description><![CDATA[Merck (MRK) recently announced that it received approval for three products in Japan. The Japanese Ministry of Health, Labour and Welfare (MHLW) approved Gardasil [human papillomavirus quadrivalent (Types 6, 11, 16 and 18) vaccine, recombinant], Zolinza (vorinostat) and Cubicin (daptomycin for injection) for use in Japan. Gardasil gained approval for the prevention of cervical cancer (squamous cell cancer and adenocarcinoma) and their precursor lesions (cervical intraepithelial neoplasm grade 1/2/3 and cervical adenocarcinoma in situ), vulvar intraepithelial neoplasia grade 1/2/3, vaginal intraepithelial neoplasia grade 1/2/3 and genital warts caused by HPV types 6, 11, 16 and 18 in females 9 years of age and older. Meanwhile, Zolinza gained approval for the treatment of cutaneous T-cell lymphomas. Cubicin, an antibacterial agent with activity against methicillin-resistant Staphylococcus aureus (MRSA), gained approval for the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/11/mrk-japanese-approval-for-merck-products/78598/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MHS) Medco Health Solutions to Better Tackle Hepatitis C</title>
		<link>http://www.stockbloghub.com/2011/07/06/mhs-medco-health-solutions-to-better-tackle-hepatitis-c/78506</link>
		<comments>http://www.stockbloghub.com/2011/07/06/mhs-medco-health-solutions-to-better-tackle-hepatitis-c/78506#comments</comments>
		<pubDate>Wed, 06 Jul 2011 21:19:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Stores]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[MedcoHealth Solutions Inc.]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MHS]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78506</guid>
		<description><![CDATA[Medco Health Solutions (MHS) is making attempts to curtail costs of treating patients suffering from hepatitis C (HCV). The company’s specialty pharmacy segment, Accredo Health Group, considers patient adherence to the treatment most significant as any contrary behavior could lead to liver cirrhosis and certain cancers. Accredo is optimistic about two new HCV medications &#8212; boceprevir and teleprevir &#8212; although the treatment process is quite complex and requires greater degree of adherence. In May 2011, Merck (MRK) received approval from the US Food and Drug Administration (FDA) for Victrelis (boceprevir) to treat chronic hepatitis C (CHC). The drug is approved for the treatment of CHC genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients who were left untreated or failed previous interferon and ribavirin therapy. The ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/06/mhs-medco-health-solutions-to-better-tackle-hepatitis-c/78506/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AAPL) Company News for July 5, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/07/05/aapl-company-news-for-july-5-2011-corporate-summary/78315</link>
		<comments>http://www.stockbloghub.com/2011/07/05/aapl-company-news-for-july-5-2011-corporate-summary/78315#comments</comments>
		<pubDate>Tue, 05 Jul 2011 14:22:04 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Personal Computers]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[AAPL]]></category>
		<category><![CDATA[Apple Inc.]]></category>
		<category><![CDATA[Central European Media Enterprises Limited]]></category>
		<category><![CDATA[CETV]]></category>
		<category><![CDATA[Darden Restaurants Inc.]]></category>
		<category><![CDATA[Dendreon Corporation]]></category>
		<category><![CDATA[DNDN]]></category>
		<category><![CDATA[DRI]]></category>
		<category><![CDATA[Eastman Kodak Company]]></category>
		<category><![CDATA[EK]]></category>
		<category><![CDATA[EMC]]></category>
		<category><![CDATA[EMC Corporation]]></category>
		<category><![CDATA[ERIC]]></category>
		<category><![CDATA[F]]></category>
		<category><![CDATA[Ford Motor Company]]></category>
		<category><![CDATA[General Motors]]></category>
		<category><![CDATA[GM]]></category>
		<category><![CDATA[Goldman Sachs Group]]></category>
		<category><![CDATA[GS]]></category>
		<category><![CDATA[Lm Ericsson Telephone Company]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[Microsoft Corporation]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MSFT]]></category>
		<category><![CDATA[Polypore International Inc]]></category>
		<category><![CDATA[PPO]]></category>
		<category><![CDATA[Research In Motion Limited]]></category>
		<category><![CDATA[RIMM]]></category>
		<category><![CDATA[SNE]]></category>
		<category><![CDATA[Sony Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=78315</guid>
		<description><![CDATA[•    Eastman Kodak Co. (NYSE:EK) received a mixed ruling from the U.S. International Trade Commission on its patent infringement suit against Research In Motion Limited (NASDAQ:RIMM) and Apple Inc. (NASDAQ:AAPL) •    Darden Restaurants, Inc. (NYSE:DRI) reported fourth quarter 2011 earnings of $1.00 per share, in line with the Zacks Consensus Estimate, but up 23% from the year-ago quarter&#8217;s earnings of 81 cents per share •    Major auto makers General Motors Company (NYSE:GM) and Ford Motor Co. (NYSE:F) both reported robust June sales figures that jumped 10% over the month. Shares of the companies gained 0.7% and 1.7%, respectively •    Reports suggested that Dendreon Corp.’s (NASDAQ:DNDN) prostate cancer medicine Provenge was recommended to be covered under Medicare •    Merck &#38; Co. Inc. (NYSE:MRK) won approval to sell its cervical cancer vaccine, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/05/aapl-company-news-for-july-5-2011-corporate-summary/78315/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(UPS) UPS-Merck Expand Deal</title>
		<link>http://www.stockbloghub.com/2011/06/29/ups-ups-merck-expand-deal/77912</link>
		<comments>http://www.stockbloghub.com/2011/06/29/ups-ups-merck-expand-deal/77912#comments</comments>
		<pubDate>Wed, 29 Jun 2011 20:52:49 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Air Delivery & Freight Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[FDX]]></category>
		<category><![CDATA[FedEx Corporation]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[United Parcel Service Inc.]]></category>
		<category><![CDATA[UPS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77912</guid>
		<description><![CDATA[United Parcel Services (UPS), the world&#8217;s largest package delivery company, inked a new deal with healthcare giant  Merck &#38; Co. Inc. (MRK) to expand its distribution and logistics services. The companies did not reveal financial terms of the deal. UPS initially began this alliance in 2003 to transport Merck’s products in the U.S. In 2009, the deal was extended to distribution, storage and transportation of medicines and vaccines in North America. The new contract expands the distribution reach further to certain Asian and Latin American markets as well as emerging markets like China and Brazil. As a part of the expansion, UPS is constructing a new distribution center in China and Brazil to market Merck products. The company has profound logistics expertise to deliver Merck&#8217;s products to several small, mid-sized ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/29/ups-ups-merck-expand-deal/77912/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(NVO) Novo Nordisk Presents Diabetes Study Data</title>
		<link>http://www.stockbloghub.com/2011/06/29/nvo-novo-nordisk-presents-diabetes-study-data/77767</link>
		<comments>http://www.stockbloghub.com/2011/06/29/nvo-novo-nordisk-presents-diabetes-study-data/77767#comments</comments>
		<pubDate>Wed, 29 Jun 2011 16:42:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[AMLN]]></category>
		<category><![CDATA[Amylin Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novo Nordisk A-S]]></category>
		<category><![CDATA[NVO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77767</guid>
		<description><![CDATA[Recently, Novo Nordisk (NVO) presented data from two extension studies of its lead diabetes drug Victoza at the American Diabetes Association. Victoza is currently marketed as a once-daily human Glucagon-Like Peptide- 1 (GLP-1) analogue for the treatment of type II diabetes. The first study showed that treatment with Victoza (once daily) in combination with metformin and/or sulfonylurea caused more patients to achieve control over their blood sugar levels compared to those treated with other commonly used diabetes drugs like Merck’s (MRK) Januvia and Amylin Pharmaceuticals’ (AMLN) Byetta. Moreover, data also revealed that patients underwent significant weight loss on switching over to Victoza therapy from Januvia. Novo Nordisk also presented data from another late stage study which investigated the effect of adding Levemir to the existing treatment regimen of Victoza and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/29/nvo-novo-nordisk-presents-diabetes-study-data/77767/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ABT) Abbott Labs Boosts Immunology Pipeline</title>
		<link>http://www.stockbloghub.com/2011/06/24/abt-abbott-labs-boosts-immunology-pipeline/77422</link>
		<comments>http://www.stockbloghub.com/2011/06/24/abt-abbott-labs-boosts-immunology-pipeline/77422#comments</comments>
		<pubDate>Fri, 24 Jun 2011 22:04:03 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[RA]]></category>
		<category><![CDATA[Railamerica Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77422</guid>
		<description><![CDATA[Abbott Labs (ABT) recently entered into a global agreement with Biotest AG for the development and commercialization of a novel anti-CD4 antibody, BT-061. The Candidate: BT-061 The deal is focused on the development and commercialization of BT-061 for the treatment of rheumatoid arthritis (RA) and psoriasis. BT-061 is currently being evaluated in phase II studies for RA and psoriasis. Moreover, the candidate’s potential to be used for other immune-related diseases is being evaluated in preclinical studies. BT-061 could be differentiated from other anti-CD4 antibodies as it does not cause depletion of CD4 positive T-cells which would lead to weakened immune responses. Terms of the Deal Per the terms of the agreement, BT-061 will be co-promoted by Abbott Labs and Biotest in the five major European markets: Germany, France, United Kingdom, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/24/abt-abbott-labs-boosts-immunology-pipeline/77422/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(VRTX) Vertex Pharmaceuticals Get Positive Data on Incivek</title>
		<link>http://www.stockbloghub.com/2011/06/24/vrtx-vertex-pharmaceuticals-get-positive-data-on-incivek/77386</link>
		<comments>http://www.stockbloghub.com/2011/06/24/vrtx-vertex-pharmaceuticals-get-positive-data-on-incivek/77386#comments</comments>
		<pubDate>Fri, 24 Jun 2011 20:36:58 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Champion Industries Inc]]></category>
		<category><![CDATA[CHMP]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[SVR]]></category>
		<category><![CDATA[Syniverse Holdings Inc.]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77386</guid>
		<description><![CDATA[Vertex Pharmaceuticals Inc. (VRTX) recently reported data from two late stage trials – ADVANCE and REALIZE – on Incivek (telaprevir). The data were published in the June edition of the New England Journal of Medicine. The trial results demonstrated that when patients suffering from chronic hepatitis C (HCV) were given Incivek combination therapy, they experienced significant improvement in sustained viral response (SVR) rates, as compared to those who received pegylated-interferon and ribavirin alone. In the ADVANCE study, Incivek combination therapy demonstrated the aforesaid results in new patients, while the REALIZE study consisted of treatment-failed patients. We note that in the ADVANCE study, majority of the patients treated with Incivek combination therapy completed the treatment in 24 weeks, which is half the time needed in the pegylated-interferon and ribavirin arm. Further, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/24/vrtx-vertex-pharmaceuticals-get-positive-data-on-incivek/77386/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(JNJ) Pharma &amp; Biotech Stock Outlook &#8211; June 2011 &#8211; Industry Outlook</title>
		<link>http://www.stockbloghub.com/2011/06/14/jnj-pharma-biotech-stock-outlook-june-2011-industry-outlook/76371</link>
		<comments>http://www.stockbloghub.com/2011/06/14/jnj-pharma-biotech-stock-outlook-june-2011-industry-outlook/76371#comments</comments>
		<pubDate>Wed, 15 Jun 2011 03:24:14 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AGN]]></category>
		<category><![CDATA[Allergan Inc.]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GILD]]></category>
		<category><![CDATA[Gilead Sciences Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Vertex Pharmaceuticals Incorporated]]></category>
		<category><![CDATA[VRTX]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=76371</guid>
		<description><![CDATA[Challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition, pipeline failures and limited late-stage catalysts continue to impact the pharmaceutical industry. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses. All these factors will lead to a slowdown in global pharmaceutical market growth in the next five years. Products like Lipitor, Plavix, Lexapro and Zyprexa are expected to face generic competition over the next five years. In fact, 2011 itself will see drugs worth more than $30 billion losing patent protection. This includes drugs like Lipitor, Zyprexa and Levaquin. The effect of the genericization of these products will be felt mostly in 2012, which will be a challenging year for several companies. At the same time, new products are ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/14/jnj-pharma-biotech-stock-outlook-june-2011-industry-outlook/76371/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PRGO) Perrigo Cruises Past Estimates &#8211; Lifts Outlook</title>
		<link>http://www.stockbloghub.com/2011/05/08/prgo-perrigo-cruises-past-estimates-lifts-outlook/73520</link>
		<comments>http://www.stockbloghub.com/2011/05/08/prgo-perrigo-cruises-past-estimates-lifts-outlook/73520#comments</comments>
		<pubDate>Sun, 08 May 2011 15:51:27 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Advanced Photonix Inc.]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73520</guid>
		<description><![CDATA[Perrigo Company (PRGO) reported earnings per share of $1.07 for the third quarter of fiscal 2011, easily beating the Zacks Consensus Estimate of 96 cents and the year-earlier earnings of 81 cents per share. Results were driven by a solid top-line performance. Third quarter revenues increased 29% over the prior year to $692 million. Total revenues were also above the Zacks Consensus Estimate of $686 million. The year-over-year revenue growth was boosted by strong performances by the company’s generic prescription and active pharmaceutical ingredient (API) businesses. New products added $44 million to revenues. The Quarter in Detail The revenue performance in the quarter from four of the company’s businesses is detailed below. Consumer Healthcare (CHC): Perrigo reported CHC revenue of $425 million in the third quarter, up 13% over the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/08/prgo-perrigo-cruises-past-estimates-lifts-outlook/73520/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AZN) AstraZeneca Revenues Fall &#8211; Outlook Improves</title>
		<link>http://www.stockbloghub.com/2011/05/03/azn-astrazeneca-revenues-fall-outlook-improves/73038</link>
		<comments>http://www.stockbloghub.com/2011/05/03/azn-astrazeneca-revenues-fall-outlook-improves/73038#comments</comments>
		<pubDate>Tue, 03 May 2011 18:03:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ADS]]></category>
		<category><![CDATA[Alliance Data Systems Corporation]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[PDL BioPharma Inc]]></category>
		<category><![CDATA[PDLI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73038</guid>
		<description><![CDATA[AstraZeneca plc (AZN) reported first-quarter fiscal 2011 core earnings of $2.23 per American Depositary Share (ADS), reflecting an increase of 10% (at constant exchange rates [CER]) from the prior-year quarter. The Zacks Consensus Estimate for the reported quarter was $2.04 per share. Including one-time items, earnings came in at $2.08, up 10%. Despite lower revenues, earnings climbed as a result of lower tax rate and lower number of shares outstanding. Revenues AstraZeneca’s first quarter revenues declined 4% year over year to $8.3 billion owing to intense generic competition and government price interventions. However, revenues were in line with the Zacks Consensus Estimate. Generic competition for major products in the US and the impact of the healthcare reform led to an 11% slide in US revenues. The Rest of the World ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/03/azn-astrazeneca-revenues-fall-outlook-improves/73038/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CAG) Company News for May 2, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/05/02/cag-company-news-for-may-2-2011-corporate-summary/72923</link>
		<comments>http://www.stockbloghub.com/2011/05/02/cag-company-news-for-may-2-2011-corporate-summary/72923#comments</comments>
		<pubDate>Mon, 02 May 2011 19:22:08 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Consumer Goods]]></category>
		<category><![CDATA[Processed & Packaged Goods]]></category>
		<category><![CDATA[CAG]]></category>
		<category><![CDATA[Chevron Corporation]]></category>
		<category><![CDATA[ConAgra Foods Inc.]]></category>
		<category><![CDATA[CVX]]></category>
		<category><![CDATA[DHI]]></category>
		<category><![CDATA[DR Horton Inc.]]></category>
		<category><![CDATA[FLEX]]></category>
		<category><![CDATA[Flextronics International Limited]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[RAH]]></category>
		<category><![CDATA[Ralcorp Holdings Inc.]]></category>
		<category><![CDATA[SPWRA]]></category>
		<category><![CDATA[Sunpower Corporation]]></category>
		<category><![CDATA[TOT]]></category>
		<category><![CDATA[Total SA]]></category>
		<category><![CDATA[Verizon Communications Inc.]]></category>
		<category><![CDATA[VZ]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=72923</guid>
		<description><![CDATA[•    Research firm  Argus downgraded Flextronics International Ltd. (NASDAQ:FLEX) from &#8220;buy&#8221; to &#8220;hold&#8221; rating •    Merck &#38; Co. Inc.&#8217;s (NYSE:MRK) earnings per share (excluding  special items) for the first quarter of 2011 came in at 92 cents, well above the Zacks Consensus Estimate of 84 cents and the year-ago earnings of 83 cents •    Aon Corporation (NYSE:AON) reported Q1 EPS of $0.80, ex-items, in line with the Zacks Consensus Estimate •    Verizon Communications Inc. (NYSE:VZ) fell after Citigroup downgraded the company from &#8220;buy to &#8220;hold&#8221; rating,&#8221; citing valuation •    ConAgra Foods, Inc. (NYSE:CAG) made an unsolicited bid for Ralcorp Holdings Inc. (NYSE:RAH), according to a report •    Chevron Corp. (NYSE:CVX) reported a jump in its first-quarter 2011 profits, benefiting from higher oil prices and stronger refining margins. Earnings per share ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/02/cag-company-news-for-may-2-2011-corporate-summary/72923/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AXP) Stock Market News for May 2, 2011 &#8211; Market News</title>
		<link>http://www.stockbloghub.com/2011/05/02/axp-stock-market-news-for-may-2-2011-market-news/72922</link>
		<comments>http://www.stockbloghub.com/2011/05/02/axp-stock-market-news-for-may-2-2011-market-news/72922#comments</comments>
		<pubDate>Mon, 02 May 2011 19:22:06 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Credit Services]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[American Express Company]]></category>
		<category><![CDATA[AXP]]></category>
		<category><![CDATA[BA]]></category>
		<category><![CDATA[Boeing Company]]></category>
		<category><![CDATA[CAT]]></category>
		<category><![CDATA[Caterpillar Inc.]]></category>
		<category><![CDATA[Chevron Corporation]]></category>
		<category><![CDATA[CVX]]></category>
		<category><![CDATA[DHI]]></category>
		<category><![CDATA[DR Horton Inc.]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[Microsoft Corporation]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[MSFT]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[United Technologies Corporation]]></category>
		<category><![CDATA[UTX]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=72922</guid>
		<description><![CDATA[Investors were in an upbeat mood after the benchmarks had their best monthly performance in years and the markets had their best run in five weeks, ended with gains on Friday. Through the week, the indices were pushed higher by the Federal Reserve’s vow to keep interest rates low to stimulate the economy and by robust quarterly results. Disappointing data could cause little damage to the markets as even on Friday, positive earnings results took precedence over modest economic data. On Friday, The Dow Jones Industrial Average (DJIA) rose 0.4% to close at 12,810.54, its highest close since May 20, 2008. The Standard &#38; Poor 500 (S&#38;P 500) gained 0.2% and finished at 1,363.61, its highest close since June 5, 2008. The Nasdaq settled at 2,873.54, gaining 0.04% and posted ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/02/axp-stock-market-news-for-may-2-2011-market-news/72922/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMGN) Amgen Beats First Quarter Estimates &#8211; Maintains Outlook</title>
		<link>http://www.stockbloghub.com/2011/04/27/amgn-amgen-beats-first-quarter-estimates-maintains-outlook/72064</link>
		<comments>http://www.stockbloghub.com/2011/04/27/amgn-amgen-beats-first-quarter-estimates-maintains-outlook/72064#comments</comments>
		<pubDate>Wed, 27 Apr 2011 17:52:52 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Amgen Inc]]></category>
		<category><![CDATA[AMGN]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=72064</guid>
		<description><![CDATA[Amgen (AMGN) reported first quarter earnings per share of $1.32, 3 cents above the Zacks Consensus Estimate of $1.29 and 3.1% above year-ago earnings. Higher revenues, a lower tax rate and lower share count helped drive first quarter results. Including one-time items, earnings increased 2% to $1.20 in the first quarter of 2011. Total revenues increased 3.2% to $3,706 million in the first quarter of 2011. Revenues topped the Zacks Consensus Estimate of $3,662 million. US revenues increased 4% during the quarter to $2,778 million. Meanwhile, international revenues dropped 1% to $840 million. Foreign exchange (Fx) fluctuation negatively impacted revenues during the first quarter. While Xgeva was off to a strong start, Epogen performance disappointed. The Quarter in Detail First quarter total product sales increased 2.6% to $3,618 million. Revenues ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/27/amgn-amgen-beats-first-quarter-estimates-maintains-outlook/72064/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MRK) Five Large Cap Pharmaceuticals to Consider</title>
		<link>http://www.stockbloghub.com/2011/04/27/mrk-five-large-cap-pharmaceuticals-to-consider/72522</link>
		<comments>http://www.stockbloghub.com/2011/04/27/mrk-five-large-cap-pharmaceuticals-to-consider/72522#comments</comments>
		<pubDate>Wed, 27 Apr 2011 17:41:27 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=72522</guid>
		<description><![CDATA[The Large Cap Pharma sector is the fastest rising sector on Barchart when screening for the 1 month price change.  The general investing public is very interested in this sector as evidenced by the 25,409 opinions expressed on Motley Fool on the 5 stocks I selected.  Before buying make sure a pharma fits into your asset allocation plan and then please do you own further due diligence.  Read my opinion at the end of this article.  Let&#8217;s look at these 5. Merck (MRK) &#8211;  a global research-driven pharmaceutical company dedicated to putting patients first. Established in 1891, Merck discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The company devotes extensive efforts to increase access to medicines through far-reaching programs that not only donate Merck medicines ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/27/mrk-five-large-cap-pharmaceuticals-to-consider/72522/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALKS) Company News for April 18, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/04/18/alks-company-news-for-april-18-2011-corporate-summary/71757</link>
		<comments>http://www.stockbloghub.com/2011/04/18/alks-company-news-for-april-18-2011-corporate-summary/71757#comments</comments>
		<pubDate>Mon, 18 Apr 2011 19:25:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alkermes Inc.]]></category>
		<category><![CDATA[ALKS]]></category>
		<category><![CDATA[BAC]]></category>
		<category><![CDATA[Bank of America Corporation]]></category>
		<category><![CDATA[BRNC]]></category>
		<category><![CDATA[Bronco Drilling Company Inc]]></category>
		<category><![CDATA[C]]></category>
		<category><![CDATA[Chesapeake Energy Corporation]]></category>
		<category><![CDATA[CHK]]></category>
		<category><![CDATA[Citigroup Inc.]]></category>
		<category><![CDATA[EBAY]]></category>
		<category><![CDATA[eBay Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[Finish Line Inc.]]></category>
		<category><![CDATA[FINL]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[ROSE]]></category>
		<category><![CDATA[Rosetta Resources Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71757</guid>
		<description><![CDATA[• Chesapeake Energy Corp&#8217;s. (NYSE:CHK) share prices gained 0.25% after it announced plans to buy Bronco Drilling Co. (NASDAQ:BRNC) for $11 a share. The purchase price represents a 24% premium over Bronco’s average 90-day closing price • A report from Bloomberg cited that eBay Inc. (NASDAQ:EBAY) gains in its bid to grow its business in China • Share prices of French chip company Sequans Communications (NYSE:SQNS) fell 17.5% to close at $8.25 on its first day of trading on the New York Stock Exchange • Share prices of Bank of America (NYSE:BAC) fell 2.36% after the banking giant reported a 36% decline in first-quarter profits as the foreclosures crisis continued to squeeze its home loan business. Bank of America is the largest U.S. bank by assets • Shares of Merck (NYSE:MRK) rose 1.92% to $34.51 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/18/alks-company-news-for-april-18-2011-corporate-summary/71757/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

